<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04324463</url>
  </required_header>
  <id_info>
    <org_study_id>PHRI.ACT.COVID19</org_study_id>
    <nct_id>NCT04324463</nct_id>
  </id_info>
  <brief_title>Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial</brief_title>
  <acronym>ACTCOVID19</acronym>
  <official_title>Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      ACT is a randomized clinical trial to assess therapies to reduce the clinical progression of
      COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ACT COVID-19 program consists of two parallel trials testing the effects of interventions
      in complementary populations in outpatients and inpatients.

      In the outpatient study, symptomatic patients in the community who are COVID-19 positive and
      at high risk of disease progression: colchicine compared with control (anti-inflammatory);
      and ASA compared with control (anti-thrombotic); using a 2 x 2 factorial design. The primary
      outcome for colchicine vs. control is the composite of hospitalization or death; and the
      co-primary outcome is disease progression by 2 points on a 7-point scale. The primary outcome
      for ASA vs. control is the composite of hospitalization or death; and the co-primary outcomes
      are the composite of major adverse cardiovascular events (MI, stroke, ALI, VTE, death), and
      disease progression by 2 points on a 7-point scale.

      For inpatients, in symptomatic patients who are COVID-19 positive and who are hospitalized:
      interferon-β is compared with control (anti-viral); colchicine is compared with control
      (anti-inflammatory); and the combination of ASA and rivaroxaban is compared with control
      (anti-thrombotic); using a 2 x 2 x 2 factorial design. The primary outcome for interferon-β
      vs. control, and for colchicine vs. control is the composite of invasive mechanical
      ventilation or death; and the co-primary outcome is disease progression by 2 points on a
      7-point scale. The primary outcome for the combination of ASA and rivaroxaban vs. control is
      the composite of invasive mechanical ventilation or death; and the co-primary outcomes are
      the composite of major adverse cardiovascular events (MI, stroke, ALI, VTE, death) and
      disease progression by 2 points on a 7-point scale.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label, parallel group, factorial, randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Outpatient trial - Colchicine vs. control and Aspirin vs. control</measure>
    <time_frame>45 days post randomization</time_frame>
    <description>composite of hospitalization or death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inpatient trial - Interferon-β vs. control and Colchicine vs. control</measure>
    <time_frame>45 days post randomization</time_frame>
    <description>invasive mechanical ventilation or death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inpatient trial - Aspirin and rivaroxaban vs. control</measure>
    <time_frame>45 days post randomization</time_frame>
    <description>invasive mechanical ventilation or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Outpatient and Inpatient trials - Colchicine vs. control, Interferon-β vs. control</measure>
    <time_frame>45 days post randomization</time_frame>
    <description>disease progression by 2 points on a 7-point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outpatient and Inpatient trials - Aspirin vs. control, Aspirin and rivaroxaban vs. control</measure>
    <time_frame>45 days post randomization</time_frame>
    <description>composite of major adverse cardiovascular events (MI, stroke, ALI, VTE, death), and disease progression by 2 points on a 7-point scale</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Coronavirus</condition>
  <condition>Severe Acute Respiratory Syndrome</condition>
  <arm_group>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Outpatients:
0.6 mg twice daily for 3 days, then 0.6 mg once daily for 25 days (total 28 days).
Inpatients:
1.2 mg followed by 0.6 mg 2 hours later, then 0.6 mg twice daily for 28 days.
(*Depending on availability, 0.6 mg tablets can be substituted by 0.5 mg tablets for a regimen in outpatients of 0.5 mg twice daily for 3 days, then 0.5 mg once daily for 25 days [total 28 days]; and in inpatients of 1.0 mg followed by 0.5 mg 2 hours later, then 0.5 mg twice daily for 28 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interferon Beta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inpatients Only:
0.25 mg by subcutaneous injection on days 1, 3, 5 &amp; 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin (ASA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Outpatients:
75 to 100 mg once daily for 28 days.
Inpatients:
75 to 100 mg once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inpatients Only:
2.5 mg twice daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care (Control)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Outpatients and Inpatients: No constraints for treating physicians on the therapies within the standard of care arm. All key co-interventions will be documented.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>oral medication</description>
    <arm_group_label>Colchicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-Beta</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>Interferon Beta</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>oral medication</description>
    <arm_group_label>Aspirin (ASA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>oral medication</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Outpatient trial:

        Inclusion criteria:

          1. Symptomatic and laboratory-confirmed diagnosis of COVID-19.

          2. Age ≥18 years.

          3. High risk: either age ≥70 or one of the following: male; obesity (BMI ≥30); chronic
             cardiovascular, respiratory or renal disease; active cancer; diabetes.

          4. Within 7 days (ideally 72 hours) of diagnosis, or worsening clinically.

        Exclusion criteria:

          1. General: advanced kidney disease; advanced liver disease; pregnancy (known or
             potential) or lactation.

          2. Colchicine: allergy or planned use; current or planned use of cyclosporine, verapamil,
             HIV protease inhibitor, azole antifungal, or macrolide antibiotic (except
             azithromycin).

          3. ASA: allergy; high risk of bleeding, current or planned use of other anti-thrombotic
             drugs (e.g., P2Y12 inhibitors, direct oral anticoagulants, vitamin K antagonists,
             heparins)

        Inpatient trial:

        Inclusion criteria:

          1. Symptomatic and laboratory-confirmed diagnosis of COVID-19.

          2. Age ≥18 years.

          3. Within 72 hours (ideally 24 hours) of admission, or worsening clinically.

        Exclusion criteria:

          1. General: advanced kidney disease; advanced liver disease, pregnancy (known or
             potential) or lactation, already ventilated for &gt;72 hours.

          2. Interferon-ß: known monoclonal gammopathy, history of severe depression/anxiety.

          3. Colchicine: allergy or planned use; current or planned use of cyclosporine, verapamil,
             HIV protease inhibitors, azole antifungals, or macrolide antibiotics (except
             azithromycin).

          4. ASA and rivaroxaban: allergy; high risk of bleeding; estimated GFR &lt;15 ml/min; current
             or planned use of P2Y12 inhibitors or therapeutic doses of anticoagulants* (e.g.,
             direct oral anticoagulants, vitamin K antagonists, heparin, LMWH), current or planned
             use of strong inhibitors of both CYP 3A4 and P-gp (e.g., lopinavir/ritonavir,
             carbamazepine, ketoconazole). *Note that prophylactic doses of anticoagulants can be
             used in patients who are randomized to control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Whitlock, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emilie Belley-Cote, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Eikelboom, MBBS MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ACT COVID-19 Study Coordinator</last_name>
    <phone>905-297-3479</phone>
    <email>ACT.ProjectTeam@PHRI.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ACT COVID-19 Study Coordinator</last_name>
      <email>ACT.ProjectTeam@PHRI.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>coronavirus</keyword>
  <keyword>interferon</keyword>
  <keyword>colchicine</keyword>
  <keyword>aspirin</keyword>
  <keyword>rivaroxaban</keyword>
  <keyword>anti-inflammatory</keyword>
  <keyword>antithrombotic</keyword>
  <keyword>anti-viral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Colchicine</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

